Tobacco smoking and cancer: The promise of molecular epidemiology

Salud Publica de Mexico

Volumn 39, Issue 4, 1997, Pages 331-345

  Wang, Sophia S ^a   Samet, Jonathan M ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidemiology; Molecular; Neoplasms; Review; Smoking

Indexed keywords

BENZO[A]PYRENE; BIOLOGICAL MARKER; TOBACCO SMOKE;

CARCINOGENESIS; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; REVIEW; SMOKING;

EID: 0030967820     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-36341997000400011     Document Type: Review

References (64)

1. US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, DHHS Publication No. (CDC) 89-8411, 1989.
2. Samet JM, Lung cancer. En Cancer prevention and control. Nueva York: Marcel Dekker, Inc., 1995.
3. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Tobacco smoking. Lyon: World Health Organization, IARC, 1986:vol.38.
4. US Department of Health and Human Services. The health consequences of smoking: Nicotine addiction. A Report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office on Smoking and Health. DHHS Publication núm. (CDC) 88-84406, 1988.
5. US Department of Health and Human Services. The health benefits of smoking cessation: A Report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, DHHS Publication núm. (CDC) 90-8416, 1990.
6. Burns DM, Garfinkel L, Samet J, ed. Changes in cigarette-related disease risks and their implication for prevention and control. Smoking and Tobacco Control Monograph 6. US Department of Health and Human Services. En prensa.
7. US Department of Health and Human Services. The health consequences of smoking: Cancer A Report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office on Smoking and Health. DHHS Publication núm. (PHS) 82-50179, 1982.
8. Harris CC. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 1991;51 suppl 18:50235-50445.
9. Vineis P. Epidemiologic models of carcinogenesis:The example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1992;1:149-153.
10. Harris CC, Reddel R, Pfeifer A et al. Role of oncogenes and tumour suppressor genes in human lung carcinogenesis. Relevance to human cancer of N-Nitroso compounds. Tobacco smoke and mycotoxins. Lyon: International Agency for Research on Cancer, 1991.
11. Colburn NH, Moses HL, Stanbridge EJ. Growth factors, tumor promoters, and cancer genes. UCLA symposia on molecular and cellular biology new series. Nueva York: Alan R. Liss, Inc., 1988:vol.58.
12. Lehman TA, Reddel R, Pfeifer A et al. Oncogenes and tumor-suppressor genes. Environ Health Perspect 1991;93:133-144.
13. Greenblatt MS, Benett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
14. International Agency for Research on Cancer. IARC Mechanisms of carcinogenesis in risk identification. World Health Organization, 1992-116.
15. Groopman JD, Skipper PL. Molecular dosimetry and human cancer: Analytical, epidemiological, and social considerations. Boca Raton: CRC Press, Inc., 1991.
16. Schulte P, Perera F. Molecular epidemiology. San Diego: Academic Press, 1993.
17. Hulka BS. Epidemiologic studies using biological markers: Issues for epidemiologists. Cancer Epidemiol Biomarkers Prev 1991;1:13-19.
18. US Department of Health and Human Services. The changing cigarette: report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Health, Office on Smoking and Health, DHHS publication núm. (PHS)81-50156, 1981.
19. Ruddon RW. Cancer biology 2a edición Nueva York: Oxford University Press, 1987.
20. Vineis P, Caporaso N. Applications of biochemical epidemiology in the study of human carcinogenesis. Tumori 1988;74:19-26.
21. Carmella SG, Kagan SS, Kagan M, Foiles PG et al. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers and non-smokers. Cancer Res 1990;50:5438-5445.
22. Hecht SS, Carmella SG, Murphy SE, Akerkar S et al. A tobacco-specific carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993;329:1543-1546.
23. Alexandrov K, Rojas M, Geneste O et al. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: Comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1993;53:6248-6251.
24. Bartsch H, Caporaso N, Coda M et al. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990;82(23):1826-1831.
25. Dunn BP, Vedal S, San RHC et al. DNA adducts in bronchial biopsies. Int J Cancer 1991;48:485-492.
26. Beach AC, Gupta RC. Human biomonitoring and the 32P-postlabeling assay. Carcinogenesis 1992;13:1053-1074
27. Davidson BJ, Hsu TC, Schantz SP. The genetics of tobacco-induced malignancy Arch Otolaryngol Head Neck Surg. 1993;119:1198-1205.
28. Vineis P, Caporaso N, Tannenbaum SR et al. Acetylation phenotype, carcinogen-hemoglobin adducts and cigarette smoking. Cancer Res 1990;50:3002-3004.
29. Talaska G, Al-Juburi AZ, Kadlubar FF. Smoking-related carcinogen-DNA adducts in biopsy samples of human urinary bladder: Identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci U S A 1991;88:5350-5354.
30. Simons AM, Phillips DH, Coleman DV. Damage to DNA in cervical epithelium related to tobacco smoking Br Med J 1993;306:1444-1448.
31. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA levels in human lungs with cigarette smoking. Nature 1988;336:790-792.
32. Mitsudomi T, Viallet J, Mulshine JL et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6:1353-1362.
33. Carbone D. Smoking and cancer. Am J Med 1992;93 suppl IA:13S-17S.
34. Chiba I, Takahashi T, Nau MM et al. Mutations in the p53 gene are frequent in primary resected non-small cell lung cancer. Oncogene 1990;5:1603-1610.
35. D'Amico D, Carbone, Mitsudomi T et al. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene 1992;7:339-346.
36. Suzuki H, Takahashi T, Kuroishi et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-736.
37. Potanovich L. Lung cancer: Prevention and detection update Semin Oncol Nurs 1993;9(3):174-179.
38. Slebox RJC, Hruban RH, Dalesio O et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-1027.
39. Largey JS, Meltzer SJ, Yin J et al. Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction. Cancer 1993;71:1933-1937.
40. Wagata T, Shibagaki I, Imamura M et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-850.
41. Somers KD, Merrick MA, López ME et al. Frequent p53 mutations in head and neck cancer. Cancer Res 1992;52:5997-6000.
42. Somers KD, Schechter GL. Genetic alterations in head and neck cancer. Otolaryngol Clin North Am 1992;25:1065-1071.
43. Spruck CH, Rideout WM, Olumi AF et al. Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 1993;53:1162-1166.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
45. Zhang ZF, Sarkis AS, Cardon-Carlo C et al. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1993;3:19-24.
46. Knowles MA, Cairns JP, Williamson MP, Proctor AJ, Coombs LM, Eydmann ME Identification of multiple molecular genetic alterations in bladder cancer Cancer Genet Cytogenet 1992;63:140.
47. Jaing W, Kahn SM, Tomita N, Zhang Y, Lu S, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-2983.
48. Kok K, Terpstra P et al. Characterization of the D8 gene which locates to 3p21, the common deletion region in lung cancer. Cancer Genet Cytogenet 1992;63:182.
49. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose Cancer Res 1991;51:5177-5180.
50. Guengerich FP. Interindividual variation in biotransformation of carcinogens: Basis and relevance. En: Molecular dosimetry and human cancer. Boca Raton: CRC Press, Inc., 1991.
51. Cloos J, Spitz MR, Schantz SP et al. Genetic susceptibility to head and neck squamous cell carcinoma. Cancer Inst 1996;88(8):530-535.
52. Idle JR. Cytochrome P45011D phenotypes and human cancer risk-Cancer Detect Prev 1989;14:275-280.
53. Cosma G, Crofts F, Currie D, Wirgin I, Toniolo P, Garte SJ. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYPIAI gene. Cancer Epidemiol 1993;2:53-57.
54. Ryberg D, Kure E, Lystad S et al. p53 mutations in lung tumors: Relationship to putative susceptibility markers for cancer. Cancer Res 1994;54:1551-1555.
55. Heckbert SR, Weiss N, Hornug SK et al. Glutathione S-transferase and epoxide hydroxylase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 1992;84:414-422.
56. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) or glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: A follow up study. Carcinogenesis 1990;11:33-36.
57. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501AI and mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-870.
58. Lafuente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human glutathione S-transferase mu deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993;68:49-54.
59. Nazar-Stewart V, Motulsky AG, Eaton DL et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993;53:2313-2318.
60. Shields PG, Bowman ED, Harrington AM et al. Polycyclic aromatic hydrocarbon-DA adducts in human lung and cancer susceptibility genes. Cancer Res 1993;53:3486-3492.
61. Brokmoller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and phi in lung cancer patients and controls. Cancer Res 1993;53:1004-1011.
62. Spitz MR, Fuegger JJ, Halabi S et al. Mutagen sensitivity in upper aerodigestive tract cancer: A case-control analysis. Cancer Epidemiol Biomarkers Prev 1993;2(4):329-333.
63. Amos CI, Caporaso NE, Weston AW. Cancer Epidemiol Biomarkers Prev 1992;1:505-513.
64. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts in lung cancer mutational hotspots in p53. Science 1996;274:430-432.